Segall Bryant & Hamill LLC Has $7.05 Million Stock Position in Qiagen N.V. (NYSE:QGEN)

Segall Bryant & Hamill LLC raised its stake in Qiagen N.V. (NYSE:QGEN) by 15.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 175,656 shares of the company’s stock after purchasing an additional 23,967 shares during the period. Segall Bryant & Hamill LLC owned 0.08% of Qiagen worth $7,053,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in QGEN. Envestnet Portfolio Solutions Inc. increased its stake in Qiagen by 3.6% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 9,816 shares of the company’s stock valued at $438,000 after purchasing an additional 341 shares during the last quarter. Pitcairn Co. grew its stake in shares of Qiagen by 5.3% in the 4th quarter. Pitcairn Co. now owns 6,996 shares of the company’s stock valued at $312,000 after purchasing an additional 354 shares during the period. Exchange Traded Concepts LLC lifted its holdings in shares of Qiagen by 2.3% in the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company’s stock valued at $716,000 after purchasing an additional 395 shares in the last quarter. Headlands Technologies LLC boosted its stake in shares of Qiagen by 2.0% in the fourth quarter. Headlands Technologies LLC now owns 19,823 shares of the company’s stock valued at $883,000 after buying an additional 397 shares during the period. Finally, LPL Financial LLC boosted its position in shares of Qiagen by 2.6% during the 4th quarter. LPL Financial LLC now owns 17,240 shares of the company’s stock worth $768,000 after purchasing an additional 432 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

QGEN has been the topic of several research analyst reports. Robert W. Baird boosted their price target on shares of Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Wall Street Zen upgraded shares of Qiagen from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 15th. Barclays assumed coverage on Qiagen in a research report on Tuesday, June 24th. They issued an “overweight” rating and a $55.00 target price on the stock. Bank of America increased their target price on Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a research report on Thursday, June 26th. Finally, Redburn Atlantic downgraded Qiagen from a “buy” rating to a “neutral” rating in a research report on Friday, April 4th. Seven analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Qiagen presently has an average rating of “Hold” and an average target price of $49.40.

Qiagen Price Performance

NYSE QGEN opened at $48.27 on Friday. The firm’s fifty day simple moving average is $45.82 and its two-hundred day simple moving average is $42.95. The company has a current ratio of 3.37, a quick ratio of 2.83 and a debt-to-equity ratio of 0.40. Qiagen N.V. has a 12-month low of $37.63 and a 12-month high of $49.30. The firm has a market capitalization of $10.73 billion, a P/E ratio of 121.03, a P/E/G ratio of 2.46 and a beta of 0.68.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.05. Qiagen had a net margin of 4.68% and a return on equity of 14.61%. The firm had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. During the same period in the previous year, the business posted $0.44 earnings per share. Qiagen’s quarterly revenue was up 5.2% on a year-over-year basis. Analysts forecast that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Qiagen Dividend Announcement

The firm also recently declared a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were given a dividend of $0.25 per share. The ex-dividend date was Wednesday, July 2nd. This represents a yield of 0.52%. Qiagen’s dividend payout ratio (DPR) is 62.50%.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.